Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia
about
Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected diseaseTransmission and epidemiology of zoonotic protozoal diseases of companion animalsNutritional supplements for patients being treated for active visceral leishmaniasisMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisKnowledge of the population about visceral leishmaniasis transmission in endemic areas near the banks of the Mossoró River in northeastern Brazil.New Insights on the Inflammatory Role of Lutzomyia longipalpis Saliva in LeishmaniasisValidation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.Causes and consequences of higher Leishmania infantum burden in patients with kala-azar: a study of 625 patients.Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010.Space-time cluster analysis of American visceral leishmaniasis in Bauru, São Paulo State, Brazil.Evaluation of a new set of recombinant antigens for the serological diagnosis of human and canine visceral leishmaniasis.Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.New insights into leishmaniasis in the immunosuppressed.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and PerspectivesVisceral Leishmaniasis - Current Treatments and Needs
P2860
Q24193697-C93539DA-FBA1-48D0-96D4-95CC64F08382Q24630763-086F22D9-5BB4-492A-BCB4-0FE0613264BAQ26471592-87DAD4B8-846A-4A87-B420-5F050260721EQ28271849-F79C9458-9315-4E20-A7D4-1E2ECEAABDA5Q35228172-E5E97F15-81E0-4833-AF4A-07BD0BBB3C37Q35838090-65C6C8E5-8F95-40EB-9EA7-7DE226B8C62FQ36730131-0F6B01A9-741D-45F4-ADC1-D31C0BD45517Q36743906-17A7641E-F5A5-4202-A4B4-F264C8F2AB2CQ37372627-BE324A1E-3563-4D05-A7D2-AEE614B53E10Q38852454-4BB4F053-0384-4851-8155-612A50245DDFQ38882958-C42C71E1-5C1A-49D7-84D8-BC2366596211Q38926936-37050451-1A89-408D-96D7-2D39D946381AQ38973977-0AA3FE29-B511-4DC3-9C53-2613C892181EQ39029668-E79D8CAD-5D74-43D3-B73A-DD4558A029F1Q39180283-089B34E4-40F3-44F2-B79E-E564C0B82210Q40070592-D0F076D4-35D7-4471-BEFE-D5564F3F4874Q42366179-D87DAE67-4D49-4AD4-A9B6-C4096352579BQ47898726-8F3C5060-8DA6-41BD-8666-120473147B0BQ53683717-DC6FCC71-F7B6-45CA-90C6-47E624A6A8F4Q54961274-8FFF5999-D3C1-4B3F-82F7-3028CE4542FCQ57166879-4479F013-EC5D-4753-82FC-95967DC05F85Q59003562-2EAF7A7C-6082-490B-83C0-67A9DC523F61
P2860
Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Who is a typical patient with ...... l, East Africa, and South Asia
@ast
Who is a typical patient with ...... l, East Africa, and South Asia
@en
Who is a typical patient with ...... l, East Africa, and South Asia
@nl
type
label
Who is a typical patient with ...... l, East Africa, and South Asia
@ast
Who is a typical patient with ...... l, East Africa, and South Asia
@en
Who is a typical patient with ...... l, East Africa, and South Asia
@nl
prefLabel
Who is a typical patient with ...... l, East Africa, and South Asia
@ast
Who is a typical patient with ...... l, East Africa, and South Asia
@en
Who is a typical patient with ...... l, East Africa, and South Asia
@nl
P2093
P2860
P50
P921
P1476
Who is a typical patient with ...... l, East Africa, and South Asia
@en
P2093
Carlos Henrique Costa
Dorcas Lamounier Costa
Manica Balasegaram
María Angeles Lima
Piero L Olliaro
Suman Rijal
P2860
P304
P356
10.4269/AJTMH.2011.10-0321
P407
P577
2011-04-01T00:00:00Z